Compound profile
GHRP-6
Limited human dataAlso known as: Growth hormone-releasing peptide 6 · His-D-Trp-Ala-Trp-D-Phe-Lys-NH2
The original growth hormone-releasing hexapeptide, discovered in 1984 and the founding compound of the entire GHRP family, including GHRP-2 and hexarelin. Known for producing the strongest appetite stimulation of the group alongside its GH-releasing effect.
Overview
GHRP-6 was discovered in 1984 by endocrinologist Cyril Bowers and colleagues, who found that certain modifications to enkephalin-like peptides produced unexpected, potent growth hormone-releasing activity unrelated to their opioid effects. That original paper established GHRP-6 as a synthetic hexapeptide that specifically triggers GH release from the pituitary without significantly affecting LH, FSH, or TSH at standard doses, work that predates the discovery of ghrelin itself by more than a decade. Ghrelin, the natural hormone that activates the same receptor, was not identified until 1999, which means GHRP-6 was studied as a GH secretagogue for years before scientists understood the endogenous system it was mimicking.
As the foundational compound in its class, GHRP-6 is the direct ancestor of GHRP-2, hexarelin, and ultimately the receptor-selective secretagogues developed afterward. It remains distinct within that family for producing the most pronounced appetite stimulation, a direct consequence of activating the same ghrelin receptor pathway that drives hunger, which has made it a subject of interest for wasting and cachexia research separate from its bodybuilding-community use as a mass-gain peptide.
It has never been approved as a drug anywhere and exists solely as a research chemical, discussed heavily in fitness and anti-aging forums but with a smaller and older body of formal clinical research than its regulatory-approved cousin GHRP-2.
Mechanism (plain language)
Activates the ghrelin receptor (GHS-R1a) on the pituitary and in the hypothalamic arcuate nucleus, triggering GH release alongside strong stimulation of orexigenic (appetite-driving) neurons.
How it works
GHRP-6 binds the ghrelin receptor on pituitary somatotrophs to stimulate GH secretion, using the same calcium-influx signaling pathway later found to be shared by natural ghrelin. Because the ghrelin receptor is also densely expressed on AgRP and neuropeptide Y neurons in the hypothalamic arcuate nucleus, activating it with GHRP-6 produces a strong, fast-onset increase in hunger, typically noticeable within 20 to 30 minutes of dosing and peaking within the first hour, which is the most consistently reported and pronounced effect across the entire GHRP family.
Alongside GH, GHRP-6 also raises cortisol and prolactin, hormones the pituitary releases through separate but adjacent signaling pathways activated by the same receptor family. Researchers studying GHRP-6 for wasting conditions have specifically leveraged the appetite-driving side effect as a potential therapeutic benefit, including a small clinical study on chronic wound healing where the compound's broader anabolic and appetite effects were explored as an adjunct to wound care.
What research suggests
The original 1980s pharmacology work reliably established GH-releasing activity in humans. Later research, including a small Cuban clinical study, explored GHRP-6 for wound healing, but robust modern human trials for fitness-relevant outcomes like body composition are largely absent.
Reported benefits
What studies, case reports, and the research literature describe, not guaranteed outcomes. The trials behind these findings are in the studies below.
Reliable GH release
As the founding compound of the GHRP family, GHRP-6 was the first synthetic peptide shown to specifically trigger dose-dependent GH release in vitro and in vivo without significantly affecting other pituitary hormones at standard doses.
Wound healing signal in a small trial
A Cuban clinical study reported that GHRP-6 improved the healing process and cosmetic outcome of wounds, a use explored given the compound's combined GH and appetite effects.
Appetite stimulation for wasting contexts
GHRP-6's pronounced appetite-driving effect, a side effect for body composition users, has been studied as a potential benefit in cachexia and wasting-disease contexts where ghrelin-mimetic hunger stimulation is therapeutically useful.
Uncertainties & risks
Much of the foundational research is decades old and used small samples focused on hormone measurements rather than long-term outcomes. Appetite stimulation, water retention, and cortisol/prolactin elevation are all downsides for people using it purely for lean mass, and there is no long-term human safety data for sustained self-administered use.
GHRP-6's defining side effect, strong appetite stimulation, is a direct and well-documented consequence of its mechanism rather than an incidental risk, and it is the main practical reason people in fitness communities cycle it differently from GHRP-2 or hexarelin. Cortisol and prolactin elevation are also consistently reported across the GHRP family and are more pronounced with GHRP-6 than with its more receptor-selective descendants. As with the rest of this compound class, it is unregulated, so purity and dosing consistency in research-chemical products are not independently verified, and there is no long-term controlled human safety data for the repeated dosing protocols common in non-clinical use.
Side effects
Commonly reported
- Strong appetite increase: The most consistently reported effect, onset within 20-30 minutes of dosing
- Cortisol elevation: Documented alongside GH release in pharmacology studies
- Prolactin elevation: Reported at higher doses
- Water retention: Anecdotally and mechanistically linked to elevated GH and cortisol, less formally studied
Reported in the cited literature, not a complete list, and not medical advice. Individual responses vary; consult a qualified professional.
STACKD study summaries
Start with our in-house roundups, plain-language synthesis of the research, with primary sources cited at the bottom of each.
Primary sources
Secondary citations for verification. Prefer the STACKD summary above for context before opening these.